Literature DB >> 10647978

Assessment of infant development during an 18-month follow-up after treatment of infections in pregnant women with cefuroxime axetil.

W Manka1, R Solowiow, D Okrzeja.   

Abstract

BACKGROUND: Choices of antibacterial for infections in pregnancy are limited because of potential risks to the fetus, particularly in the early months. However, infections may result in preterm labour or other problems and so treatment is needed. Increasingly, resistance is reported among common pathogens to older agents, such as ampicillin or amoxicillin, that have been widely used in pregnancy.
OBJECTIVE: To assess the safety and efficacy of cefuroxime axetil in the treatment of infections during pregnancy.
DESIGN: This was a retrospective analysis of case records for women who were treated with cefuroxime axetil at some point during pregnancy.
SETTING: Patients were treated at one centre in Lubliniec, Poland in 1996 and 1997. PATIENTS AND PARTICIPANTS: The study included 78 women aged 19 to 38 years (mean 26 years) and their 80 infants. MAIN OUTCOME MEASURES AND
RESULTS: Efficacy in treating maternal infections was assessed, and the physical and mental development of children born to treated mothers was evaluated for at least 18 months after birth. 13 women were treated in the first trimester, 19 in the second trimester and 46 in the third trimester. There were no abnormalities causing concern in terms of physical or mental development in any of the children, and no abnormality that was attributable to the treatment the mother had received.
CONCLUSIONS: The results add clinical support for the use of cefuroxime axetil in pregnancy if an antibacterial is needed, thus offering an alternative if antibacterial resistance to older agents is an issue for the pregnant mother.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10647978     DOI: 10.2165/00002018-200022010-00007

Source DB:  PubMed          Journal:  Drug Saf        ISSN: 0114-5916            Impact factor:   5.606


  9 in total

Review 1.  ABC of labour care: care of the newborn in the delivery room.

Authors:  P Hamilton
Journal:  BMJ       Date:  1999-05-22

2.  A clinical study of cefuroxime in neonates.

Authors:  P J Wilkinson; B H Belohradsky; W Marget
Journal:  Proc R Soc Med       Date:  1977

3.  Antibiotics.

Authors:  R Wise
Journal:  Br Med J (Clin Res Ed)       Date:  1987-01-03

Review 4.  Pharmacokinetics and safety of antimicrobial agents during pregnancy.

Authors:  A W Chow; P J Jewesson
Journal:  Rev Infect Dis       Date:  1985 May-Jun

5.  Placental transfer of cefuroxime.

Authors:  I Craft; B M Mullinger; M R Kennedy
Journal:  Br J Obstet Gynaecol       Date:  1981-02

6.  Cefuroxime: potential use in pregnant women at term.

Authors:  P Bousfield; A K Browning; B M Mullinger; M Elstein
Journal:  Br J Obstet Gynaecol       Date:  1981-02

7.  Cefuroxime in the treatment of neonates.

Authors:  J de Louvois; A Mulhall; R Hurley
Journal:  Arch Dis Child       Date:  1982-01       Impact factor: 3.791

8.  Antibiotic resistance in bacterial urinary tract infections, 1991 to 1997.

Authors:  I E Dyer; T M Sankary; J A Dawson
Journal:  West J Med       Date:  1998-11

Review 9.  Cefuroxime axetil. A review of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy.

Authors:  C M Perry; R N Brogden
Journal:  Drugs       Date:  1996-07       Impact factor: 9.546

  9 in total
  3 in total

Review 1.  Antibacterial use in pregnancy.

Authors:  T M Weller; E N Rees
Journal:  Drug Saf       Date:  2000-05       Impact factor: 5.606

Review 2.  Diagnosis and treatment of allergic rhinitis and sinusitis during pregnancy and lactation.

Authors:  Gary A Incaudo
Journal:  Clin Rev Allergy Immunol       Date:  2004-10       Impact factor: 8.667

3.  Antibiotic resistance rates and physician antibiotic prescription patterns of uncomplicated urinary tract infections in southern Chinese primary care.

Authors:  Carmen Ka Man Wong; Kenny Kung; Philip Lung Wai Au-Doung; Margaret Ip; Nelson Lee; Alice Fung; Samuel Yeung Shan Wong
Journal:  PLoS One       Date:  2017-05-09       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.